Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer
• CE marked test for patients with pancreatic ductal adenocarcinoma
• Prediction of response to first-line gemcitabine-based chemotherapy
• Developed and validated with real world data and samples